Brugada syndrome drugs to avoid: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
{| cellspacing="2" cellpadding="3" border="0"
{| cellspacing="2" cellpadding="3" border="0"
|-
|-
| Generic name
| '''Generic name'''
| Brand name®
| '''Brand name®'''
| Class / Clinical use
| '''Class / Clinical use'''
| References
| '''References'''
| Recommendation
| '''Recommendation'''
|-
|-
| [http://www.drugbank.ca/drugs/DB01426 Ajmaline]
| [http://www.drugbank.ca/drugs/DB01426 Ajmaline]

Revision as of 22:56, 13 October 2012

Brugada syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Brugada syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Examples of Type I Brugada Syndrome

Chest X Ray

Echocardiography or Ultrasound

Electrophysiologic Studies

Genetic Testing

Treatment

Treatment

Drugs to Avoid

Drugs to Preferably Avoid

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brugada syndrome drugs to avoid On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brugada syndrome drugs to avoid

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brugada syndrome drugs to avoid

CDC on Brugada syndrome drugs to avoid

Brugada syndrome drugs to avoid in the news

Blogs on Brugada syndrome drugs to avoid

Directions to Hospitals Treating Brugada syndrome

Risk calculators and risk factors for Brugada syndrome drugs to avoid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The following drugs should be avoided in patients with Brugada syndrome. [1][2]

Generic name Brand name® Class / Clinical use References Recommendation
Ajmaline e.g.
Gilurytmal®
- more brand names here -
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias Brugada 1997
Rolf 2003
Wolpert 2005
Bébarová 2005
Class I
Flecainide e.g.
Tambocor®
- more brand names here -
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias Krishnan 1998
Brugada 2000
Gasparini 2003
Meregalli 2006
Stokoe 2007
Class I
Pilsicainide e.g.
Sunrhythm®
- more brand names here -
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias Takenaka 1999
Fujiki 1999
Takagi 2002
Kimura 2004
Class I
Procainamide e.g.
Procan®
Pronestyl®
- more brand names here -
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias Miyazaki 1996
Brugada 1997
Joshi 2007
Villemaire 1992
Class I
Propafenone e.g.
Rythmol®
- more brand names here -
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias Matana 2000
Akdemir 2002
Hasdemir 2006
Shan 2008
Stark 1996
Class IIa

Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.

References

  1. www.brugadadrugs.org
  2. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA (2009). "Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)". Heart Rhythm : the Official Journal of the Heart Rhythm Society. 6 (9): 1335–41. doi:10.1016/j.hrthm.2009.07.002. PMC 2779019. PMID 19716089. Retrieved 2012-10-13. Unknown parameter |month= ignored (help)